A brand of liraglutide, a daily-injection GLP-1 receptor agonist approved for type 2 diabetes and made by Novo Nordisk.
Updated Jul 18, 2026
Victoza is the brand name for liraglutide when it is prescribed for type 2 diabetes. It is a GLP-1 receptor agonist made by Novo Nordisk and is given as a once-daily subcutaneous injection.
The same medication is sold as Saxenda at higher doses for chronic weight management.
victozaliraglutideglp-1medicationglossary
Was this helpful?
Related terms
Saxenda — A brand of liraglutide, a daily-injection GLP-1 receptor agonist approved for chronic weight management and made by Novo Nordisk.
Liraglutide — A first-generation GLP-1 receptor agonist taken as a daily injection, sold as Victoza for type 2 diabetes and Saxenda for weight management.
DPP-4 — Dipeptidyl peptidase-4, the enzyme that rapidly breaks down the body's own GLP-1 within minutes.
Gastric emptying — The rate at which the stomach passes its contents into the small intestine, which GLP-1 medications slow down.
Liraglutide (Victoza and Saxenda): how the daily GLP-1 differs — Liraglutide (Victoza for diabetes, Saxenda for weight) is the first-generation GLP-1 — a daily injection with a roughly 13-hour half-life and generally more modest weight loss than the weekly drugs. Here's what makes it distinct and why it's still worth considering.